

Krzysztof Giannopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7245610/publications.pdf>

Version: 2024-02-01

134
papers

2,178
citations

304743

22
h-index

254184

43
g-index

139
all docs

139
docs citations

139
times ranked

3317
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 558.	3.7	6
2	Programmed Cell Death-1 and Its Ligands as Targets for Therapy of Multiple Myeloma Patients. <i>Cancer Management and Research</i> , 2022, Volume 14, 1267-1281.	1.9	0
3	ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8001-8001.	1.6	2
4	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021, 137, 1365-1376.	1.4	72
5	Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma. <i>Cells</i> , 2021, 10, 411.	4.1	7
6	In vivo, ex vivo and in vitro dasatinib activity in chronic lymphocytic leukemia. <i>Oncology Letters</i> , 2021, 21, 285.	1.8	4
7	Aberrant Expression of TLR2, TLR7, TLR9, Splicing Variants of TLR4 and MYD88 in Chronic Lymphocytic Leukemia Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 867.	2.4	5
8	The prognostic impact of CD49d protein and mRNA expression in patients with chronic lymphocytic leukaemia. <i>Archives of Medical Science</i> , 2021, , .	0.9	0
9	The Predominant Prognostic Significance of NOTCH1 Mutation Defined by Emulsion PCR in Chronic Lymphocytic Leukemia. <i>Cancer Management and Research</i> , 2021, Volume 13, 3663-3674.	1.9	2
10	Treatment-Free Remissionâ€”A New Aim in the Treatment of Chronic Myeloid Leukemia. <i>Journal of Personalized Medicine</i> , 2021, 11, 697.	2.5	6
11	Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutationsâ€”NOTCH1, SF3B1, MYD88, BIRC3. <i>Journal of Clinical Medicine</i> , 2021, 10, 3735.	2.4	7
12	Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study. <i>Targeted Oncology</i> , 2021, 16, 761-771.	3.6	5
13	Gene Expression Profiling Predicts Sensitivity of Chronic Lymphocytic Leukemia Cells to Dasatinib. <i>HemaSphere</i> , 2021, 5, e514.	2.7	0
14	Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group. <i>Journal of Clinical Medicine</i> , 2021, 10, 5504.	2.4	1
15	Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. <i>Anticancer Research</i> , 2020, 40, 4059-4066.	1.1	8
16	Expression and Clinical Significance of Neuropilin-1 in Patients With Multiple Myeloma. <i>Anticancer Research</i> , 2020, 40, 5437-5443.	1.1	2
17	Cofilin-1 Maintains Prosurvival Signaling in Chronic Lymphocytic Leukemia Cells. <i>Anticancer Research</i> , 2020, 40, 6327-6335.	1.1	0
18	The Application of CAR-T Cells in Haematological Malignancies. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 34.	2.3	19

#	ARTICLE	IF	CITATIONS
19	<p>Mean Platelet Volume Has Prognostic Value in Chronic Lymphocytic Leukemia</p>. Cancer Management and Research, 2020, Volume 12, 9977-9985.	1.9	8
20	Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Na~ve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study. Blood, 2020, 136, 37-39.	1.4	37
21	Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma. Advances in Medical Sciences, 2019, 64, 349-355.	2.1	16
22	Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia. Journal of Clinical Medicine, 2019, 8, 236.	2.4	49
23	Analysis of circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) in psoriatic patients. Postepy Dermatologii I Alergologii, 2019, 36, 167-172.	0.9	3
24	Deregulation of the immune system in patients with chronic lymphocytic leukemia. Postepy Higieny I Medycyny Doswiadczalnej, 2019, 73, 117-132.	0.1	1
25	Stosowanie lek~w biopodobnych w hematoonkologii ~ stanowisko Polskiego Towarzystwa Hematolog~w i Transfuzjolog~w. Acta Haematologica Polonica, 2019, 50, 51-56.	0.3	0
26	The prognostic value of mean platelet volume in cancer patients. Acta Haematologica Polonica, 2019, 50, 154-158.	0.3	1
27	Wyzwania wczesnej diagnostyki szpiczaka plazmocytowego ~ algorytm diagnostyczny. Acta Haematologica Polonica, 2019, 50, 121-129.	0.3	0
28	Diagnostyka gor~czki u pacjentki z rozpoznaniem przewlek~ej bia~aczki limfocytowej. Acta Haematologica Polonica, 2019, 50, 174-179.	0.3	0
29	Prognostic impact of NOTCH1 and MYD88 mutations in chronic lymphocytic leukemia patients. Journal of Transfusion Medicine, 2019, 12, 101-108.	0.2	0
30	Zmiany genetyczne w ch~oniaku rozlanym z du~ych kom~rek B. Acta Haematologica Polonica, 2019, 50, 204-214.	0.3	1
31	DNA methylation signature in blood does not predict calendar age in patients with chronic lymphocytic leukemia but may alert to the presence of disease. Forensic Science International: Genetics, 2018, 34, e15-e17.	3.1	13
32	Optogenetics in cancer drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 459-472.	5.0	9
33	Expression of <sc>CD</sc>274 (<sc>PD</sc>~1) is associated with unfavourable recurrent mutations in <sc>AML</sc>. British Journal of Haematology, 2018, 183, 822-825.	2.5	16
34	Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis. Postepy Dermatologii I Alergologii, 2018, 35, 344-350.	0.9	15
35	Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. Haematologica, 2018, 103, 1843-1852.	3.5	8
36	The expression of selected molecular markers of immune tolerance in psoriatic patients. Advances in Clinical and Experimental Medicine, 2018, 27, 721-725.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2018/2019. Acta Haematologica Polonica, 2018, 49, 157-206.	0.3	4
38	Immunoterapia z uÅ¼yciem przeciwciaÅ, monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych. Acta Haematologica Polonica, 2018, 49, 207-227.	0.3	5
39	Znaczenie minimalnej choroby resztkowej w szpiczaku plazmocytoowym â€” Stanowisko Polskiego Konsorcjum Szpiczakowego. Hematologia, 2018, 8, 246-254.	0.0	1
40	Praktyka kliniczna oceny minimalnej choroby resztkowej u chorych na szpiczaka plazmocytoowego w Polsce: badanie ankietowe Polskiego Konsorcjum Szpiczakowego. Hematologia, 2018, 8, 239-245.	0.0	1
41	Szczepienia ochronne u dorosÅ,ych chorych na nowotwory hematologiczne oraz u chorych z aspleniÄ... â€” zalecenia PTHiT i sekcji do spraw zakaÅ¼eÅ, PALG. Acta Haematologica Polonica, 2018, 49, 93-101.	0.3	5
42	Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. Leukemia and Lymphoma, 2017, 58, 2089-2100.	1.3	12
43	A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry. American Journal of Hematology, 2017, 92, E125-E128.	4.1	24
44	Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG). Leukemia and Lymphoma, 2017, 58, 2485-2488.	1.3	34
45	HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood, 2017, 130, 1628-1638.	1.4	40
46	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2017. Acta Haematologica Polonica, 2017, 48, 55-103.	0.3	5
47	Iksazomib u chorych z nawrotowym lub opornym na leczenie szpiczakiem plazmocytoowym. Acta Haematologica Polonica, 2017, 48, 160-164.	0.3	0
48	Rytuksymab â€” pierwsze biopodobne przeciwciaÅ,a monoklonalne w hematologii. Acta Haematologica Polonica, 2017, 48, 269-273.	0.3	1
49	Analiza skutecznoÅci ibrutinibu w podgrupie chorych na przewlekÄ... biaÅ,aczkÄ™ limfocytowÄ... z delecjÄ... 17p: badanie obserwacyjne Polskiej Grupy ds. Leczenia BiaÅ,aczek u DorosÅ,ych (PALG). Acta Haematologica Polonica, 2017, 48, 330-337.	0.3	1
50	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLLâ€”another piece in the puzzle. Annals of Hematology, 2017, 96, 33-50.	1.8	26
51	Suppressed Programmed Death 1 Expression on CD4⁺ and CD8⁺ T Cells in Psoriatic Patients. Mediators of Inflammation, 2017, 2017, 1-8.	3.0	17
52	Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia. Oncotarget, 2017, 8, 95163-95175.	1.8	7
53	Prognostic impact of NOTCH1, MYD88 and SF3B1 mutations in Polish population of chronic lymphocytic leukemia patients. Polish Archives of Internal Medicine, 2017, 127, 238-244.	0.4	9
54	Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis. Polish Archives of Internal Medicine, 2017, 127, 815-822.	0.4	11

#	ARTICLE	IF	CITATIONS
55	Novel prognostic molecular factors: a quantum leap in the field of chronic lymphocytic leukemia. <i>Folia Histochemica Et Cytobiologica</i> , 2017, 55, 95-106.	1.5	1
56	Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. <i>Oncotarget</i> , 2016, 7, 56726-56736.	1.8	58
57	Laccase purified from <i>Cerrena unicolor</i> exerts antitumor activity against leukemic cells. <i>Oncology Letters</i> , 2016, 11, 2009-2018.	1.8	32
58	Specific cytotoxic T cell immune responses against autoantigens recognized by chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2016, 174, 582-590.	2.5	3
59	Metformina: stary lek w nowej aplikacji. <i>Acta Haematologica Polonica</i> , 2016, 47, 139-145.	0.3	1
60	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej, białaczki limfocytowej w 2016 r. – Raport Grupy Roboczej PTHiT i PALG-CLL. <i>Acta Haematologica Polonica</i> , 2016, 47, 169-183.	0.3	1
61	Indirect induction of regulatory T cells accompanies immune responses during peptide vaccination of chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2016, 174, 155-157.	2.5	1
62	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytozowego oraz innych dyskracji plazmocytozowych na rok 2016. <i>Acta Haematologica Polonica</i> , 2016, 47, 39-85.	0.3	10
63	Accumulation of CD5+CD19+ B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils. <i>Clinical and Experimental Medicine</i> , 2016, 16, 503-509.	3.6	7
64	PD1/PD1L pathway, HLA-G and T regulatory cells as new markers of immunosuppression in cancers. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2016, 70, 1044-1058.	0.1	14
65	Terapia metronomiczna w hematologii: nadzieje i fakty. <i>Acta Haematologica Polonica</i> , 2015, 46, 353-358.	0.3	0
66	Dziesiątymciolecie Polskiej Grupy Szpiczakowej – historia i osiągnięcia. <i>Acta Haematologica Polonica</i> , 2015, 46, 212-223.	0.3	0
67	The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2908-2913.	1.3	18
68	Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen. <i>Leukemia and Lymphoma</i> , 2015, 56, 808-810.	1.3	9
69	Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia. <i>Acta Haematologica</i> , 2015, 134, 255-262.	1.4	38
70	Obinutuzumab jako nowa szansa terapeutyczna dla chorych na przewlekłą białaczkę limfocytową. <i>Acta Haematologica Polonica</i> , 2015, 46, 35-41.	0.3	0
71	Peptide-based immunotherapy in multiple myeloma. <i>Acta Haematologica Polonica</i> , 2015, 46, 248-253.	0.3	0
72	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytozowego oraz innych dyskracji plazmocytozowych na rok 2015. <i>Acta Haematologica Polonica</i> , 2015, 46, 159-211.	0.3	0

#	ARTICLE	IF	CITATIONS
73	The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2015, 63, 435-449.	2.3	183
74	Cytotoxic Activity of Valproic Acid on Primary Chronic Lymphocytic Leukemia Cells. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 55-62.	1.4	6
75	Association between increased levels of regulatory T cells and soluble human leukocyte antigen G with the prevalence of cancer in kidney transplant recipients. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 779-782.	0.4	1
76	Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance. <i>European Journal of Haematology</i> , 2014, 92, 91-101.	2.2	20
77	Biology and management of myeloma-related bone disease. <i>Acta Haematologica Polonica</i> , 2014, 45, 107-121.	0.3	1
78	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2014 r. – raport Grupy Roboczej PTHiT oraz PALG – CLL. <i>Acta Haematologica Polonica</i> , 2014, 45, 221-239.	0.3	3
79	The role of Th17 cells in tumor immunity. <i>Acta Haematologica Polonica</i> , 2014, 45, 155-160.	0.3	3
80	Thalidomide Regulation of NF- κ B Proteins Limits Tregs Activity in Chronic Lymphocytic Leukemia. <i>Advances in Clinical and Experimental Medicine</i> , 2014, 23, 25-32.	1.4	12
81	NPM1 Splice Variant R2 Reveals Biological and Clinical Consequences of Prognostic Value in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2338-2338.	1.4	0
82	SK053, an Inhibitor of Enzymes Involved in Allosteric Disulfide Bonds Formation, Targets Expression of Histone Genes and Induces Differentiation of Human AML Cell. <i>Blood</i> , 2014, 124, 3503-3503.	1.4	0
83	Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients. <i>Human Immunology</i> , 2013, 74, 1592-1597.	2.4	16
84	The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2013, 133, 1489-1496.	5.1	44
85	Antigen stimulation in the development of chronic lymphocytic leukemia. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2013, 67, 1204-1213.	0.1	3
86	In Chronic Lymphocytic Leukemia PD-1 Is Expressed Independently From PDCD1 Gene Polymorphisms and Does Not Influence BCR Signaling. <i>Blood</i> , 2013, 122, 1625-1625.	1.4	1
87	The Nucleophosmin-1 Splice Variant Analysis Provides More Important Information On Prognosis Than NPM1 Mutational Status In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2563-2563.	1.4	0
88	High Expression Of Cereblon (CRBN) Is Associated With Achievement Of Complete Response To Thalidomide Plus Fludarabine Regimen In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4934-4934.	1.4	0
89	Involvement Of Autoreactive T Lymphocytes In Pathogenesis Of Chronic Lymphocytic Leukemia (CLL): Specific T-Cell Immune Responses Against Autoantigens Recognized By CLL Cells. <i>Blood</i> , 2013, 122, 2859-2859.	1.4	0
90	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego na rok 2012. <i>Acta Haematologica Polonica</i> , 2012, 43, 7-47.	0.3	5

#	ARTICLE	IF	CITATIONS
91	Znaczenie receptora programowanej Āmierci 1 oraz jego ligandĀ ³ w w ukĀ,adzie immunologicznym oraz nowotworach. <i>Acta Haematologica Polonica</i> , 2012, 43, 132-145.	0.3	11
92	Immunotherapeutical approaches for multiple myeloma. <i>Acta Haematologica Polonica</i> , 2012, 43, 68-74.	0.3	0
93	Expression of soluble HLA-G in multiple myeloma patients and patients with renal failure. <i>Leukemia Research</i> , 2012, 36, 881-883.	0.8	10
94	Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2012, 7, e35178.	2.5	68
95	Treating chronic lymphocytic leukemia with thalidomide and lenalidomide. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2857-2864.	1.8	19
96	Polymorphisms of Mir-34b/c, Mir-146a and Mir-196a-2 and Predisposition to Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2011, 118, 4585-4585.	1.4	3
97	Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia. <i>Folia Histochemica Et Cytobiologica</i> , 2011, 49, 161-167.	1.5	9
98	Tyrosine kinase inhibitors in hematological malignancies. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2011, 65, 819-828.	0.1	15
99	High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. <i>Haematologica</i> , 2010, 95, 1191-1197.	3.5	124
100	Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. <i>British Journal of Haematology</i> , 2010, 148, 948-950.	2.5	55
101	Clinical Relevance of Vascular Endothelial Growth Factor Type A (VEGFA) and VEGF Receptor Type 2 (VEGFR2) Gene Polymorphism In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 4467-4467.	1.4	0
102	The Frequency of T Regulatory Cells Modulates the Survival of Multiple Myeloma Patients: Detailed Characterization of Immune Status In Multiple Myeloma. <i>Blood</i> , 2010, 116, 984-984.	1.4	1
103	<i>CD38</i>Gene Polymorphisms Contribute to Genetic Susceptibility to B-Cell Chronic Lymphocytic Leukemia: Evidence from Two Case-Control Studies in Polish Caucasians. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 945-953.	2.5	32
104	Identification of RHAMM-Derived CD8+ Restricted, Heteroclitical, Cryptic Epitope R9Y as a Promising Target for Immunotherapy of Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 3034-3034.	1.4	1
105	Co-Existing Serological Immune Responses against RHAMM Might Be a Prerequisite for Strong Cellular Immune Responses of CD8-Positive T Cells in RHAMM-R3 Peptide Vaccination for Patients with Different Hematological Malignancies.. <i>Blood</i> , 2009, 114, 3671-3671.	1.4	0
106	Neuropilin-1 ĀNovel, Promising Target for Chronic Lymphocytic Leukemia patients.. <i>Blood</i> , 2009, 114, 4392-4392.	1.4	1
107	Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. <i>Transfusion</i> , 2008, 48, 861-870.	1.6	20
108	RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. <i>Blood</i> , 2008, 111, 1357-1365.	1.4	202

#	ARTICLE	IF	CITATIONS
109	Peptide Vaccination Induces Dynamic Changes in CD4+ and CD8+ T Cell Subsets: Report on the First Peptide Vaccination Trial in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2008, 112, 3159-3159.	1.4	2
110	Dendritic cells based immunotherapy of patient with chondrosarcoma--case report.. <i>Folia Histochemica Et Cytobiologica</i> , 2008, 46, 165-70.	1.5	4
111	Molecular and Immunological Effects of Thalidomide in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008, 112, 2092-2092.	1.4	5
112	The Leukemia-Associated Antigen PRAME Is Overexpressed in Myeloid Leukemias and Inhibits Cell Differentiation by Blocking the Receptor for Retinoic Acid (RAR)-Signaling in Vitro and Is Therefore a Interesting Candidate for Targeted Immunotherapies.. <i>Blood</i> , 2008, 112, 1524-1524.	1.4	0
113	Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. <i>Oncology Reports</i> , 2008, 20, 677-82.	2.6	90
114	Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. <i>International Journal of Oncology</i> , 2007, , .	3.3	15
115	Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2007, 31, 411-412.	0.8	10
116	Large-scale generation of autologous dendritic cells for immunotherapy in patients with acute myeloid leukemia. <i>Transfusion</i> , 2007, 47, 1588-1594.	1.6	10
117	Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.. <i>Blood</i> , 2007, 110, 1806-1806.	1.4	9
118	Thalidomide Alone and in Combination with Fludarabine Exerts Distinct Molecular and Antileukemic Effects in B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007, 110, 3124-3124.	1.4	2
119	Vaccination of B-CLL Patients with Autologous Dendritic Cells Results in Immunological and Clinical Responses.. <i>Blood</i> , 2007, 110, 2052-2052.	1.4	0
120	Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. <i>International Journal of Oncology</i> , 2007, 31, 1133-9.	3.3	22
121	Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 2028-2036.	1.3	18
122	Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. <i>International Journal of Oncology</i> , 2006, 28, 855.	3.3	27
123	Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. <i>Blood</i> , 2006, 108, 4109-4117.	1.4	177
124	Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. <i>Experimental Hematology</i> , 2006, 34, 1709-1719.	0.4	41
125	Comparison of methods for determining zeta-chain associated protein " 70 (ZAP-70) expression in patients with B-cell chronic lymphocytic leukemia (B-CLL). <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 293-301.	1.5	15
126	High Frequency of T Regulatory Cells in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Is Decreased by Thalidomide and Fludarabine Treatment.. <i>Blood</i> , 2006, 108, 2108-2108.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Clinical Efficacy and Safety of Combined Thalidomide and Fludarabine Therapy in B-Cell Chronic Lymphocytic Leukemia Patients.. Blood, 2006, 108, 4975-4975.	1.4	0
128	RHAMM/CD168-R3 Peptide Vaccination of Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM) Elicits Immunological and Clinical Responses.. Blood, 2006, 108, 409-409.	1.4	0
129	Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) Correlated with Specific T Cell Responses and Survival.. Blood, 2006, 108, 414-414.	1.4	0
130	Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood, 2005, 106, 938-945.	1.4	105
131	RHAMM/CD168-R3 Peptide Vaccination of HLA-A2+ Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM).. Blood, 2005, 106, 2781-2781.	1.4	7
132	The Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) Is a Potential Target for Immunotherapy of Patients with B-Cell Chronic Lymphocytic Leukemia.. Blood, 2005, 106, 53-53.	1.4	1
133	Chronic Myeloid Leukemia (CML) Cells Express Tumor Associated Antigens Eliciting Specific CD8+ T Cell Responses Despite of Deficient Expression of Costimulatory Molecules.. Blood, 2005, 106, 2886-2886.	1.4	0
134	Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients. International Journal of Cancer, 0, , .	5.1	13